Welcome to MultiCell Technologies, Inc.

MultiCell Technologies Releases CEO Letter to Shareholders

Company Details Therapeutics Programs and Updates Investors on Recent Achievements

SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today released a letter to shareholders from Chief Executive Officer, Dr. Stephen Chang.

Following is the text of Dr. Chang's Letter to Shareholders:

Dear Valued Investor,

During the past year your company has made exciting progress

towards becoming an integrated biopharmaceutical company. Our unique

drug development technology platforms, designed to treat disease by

modulation of the human immune system have grown to include deadly

diseases such as cervical cancer and other cancers that are caused by

viruses. The most exciting aspect of this work is how we administered

MCT-465 and IgNP after the tumor had grown to a very large size in the

animal, and observed complete destruction of the tumor by the animal's

immune system. We were able to overcome cancer's ability to hide from

detection by the animal's immune system.

MultiCell's drug development technology platforms include Toll-like

Receptor (TLR) and T-cell targeting technologies designed to modulate

both the innate and adaptive immune systems, thus enabling the

creation of advanced drug candidates that stimulate or suppress the

immune system via disease specific targeting.

As a shareholder, you can expect MultiCell to continue innovating with

scientific advances focusing on the development of breakthrough drugs

to treat serious autoimmune diseases. Among those therapies under

development are drugs designed to treat multiple sclerosis and type-1

diabetes, as well as influenza. Currently, the market for therapies

that address these diseases is estimated at $8 billion worldwide. The

new therapeutic combination further expands our potential therapeutic

development targets to include cancer.

In particular, we are focused on the development of MCT-125, MCT-175,

MCT-275, and MCT-465.

MCT-125 is a first-in-class drug for treatment of chronic fatigue in

patients with multiple sclerosis. Currently there are no FDA approved

drugs for the treatment of fatigue in patients with MS. We are

presently seeking allowance to proceed from the UK's Medicine

Healthcare Product Regulatory Agency (MHRA) for approval to proceed

with our planned Phase IIb clinical trial.

MCT-175 is based on our Ig-peptide T-cell targeting technology

platform, and is indicated for the treatment of relapsing-remitting

MS. MCT-175, in preclinical development, targets disease specific

autoaggressive T-cells that destroy the myelin sheath of nerve cells.

MCT-175 successfully ameliorated the disease in animal models.

MCT-275 is also based on our Ig-peptide T-cell targeting technology

platform, and is indicated for the treatment of early on-set type-1

diabetes. In preclinical animal modes, MCT-275 lowered blood sugar

levels to within normal range, and prevented death in the experimental

group compared to the control group where all animals died as a result

of the excessive blood sugar levels.

MCT-465 is a TLR agonist, and is being developed as an adjuvant

therapy for the treatment of virus infection and cancer. MCT-465 in

preclinical studies successfully reduced pulmonary influenza virus

levels 1,000-fold in animal models, and has demonstrated effectiveness

in reducing virus levels of HIV and HCV in animal models. In

preclinical animal studies, MCT-465 successfully eliminated certain

types of cancers caused by viruses.

Moving forward, our shareholders can expect us to continue expanding

our portfolio of platform drug development technologies and

prospective new drug candidates.

Thank you for your continued support.

Yours sincerely,

Dr. Stephen Chang

CEO, MultiCell Technologies, Inc.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:

MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.
MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.
MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models.

The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics.

For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.

Contact:

MultiCell Technologies, Inc.
Dr. Stephen Chang
MCETInvestor@MultiCelltech.com

or

Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com

Source: Business Wire (Monday November 27, 4:01 pm ET)